Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations

• Published in: Future oncology (London, England) England), 2021-08, Vol.17 (22), p.2867-2881
• Main Authors: Winfree, Katherine B, Molife, Cliff, Peterson, Patrick M, Chen, Yongmei, Visseren-Grul, Carla M, Leusch, Mark S, Beyrer, Julie, Dimou, Anastasios
• Format: Article
• Language: English
• Subjects: Adult; Aged; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - mortality; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Exons - genetics; Female; Follow-Up Studies; Humans; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Retrospective Studies
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2021-0218

To estimate real-world (rw) outcomes for first-line therapy in patients with advanced EGF receptor ( )-mutated non-small-cell lung cancer (NSCLC), focusing on specific mutation types. Retrospective observational study (n = 244 patients). Univariate/multivariate analyses showed longer rw progression-free survival (rwPFS) and rwPFS2 in patients with ex19del versus Leu858Arg mutations. Median overall survival was 12.3 months longer with ex19del versus Leu858Arg mutations (HR: 1.47 [95% CI: 0.96-2.25]; p = 0.074). With EGFR-tyrosine kinase inhibitor monotherapy, unadjusted rwPFS for ex19del mutations was longer than for Leu858Arg mutations (HR: 1.62 [95% CI: 1.03-2.56]; p = 0.036). In this rw cohort of patients with advanced + NSCLC, ex19del mutations conferred a prognostic advantage over Leu858Arg mutations, with significantly better rwPFS and rwPFS2.